Skip to main content
. 2018 Jul 4;362:k2505. doi: 10.1136/bmj.k2505

Table 4.

Patients without atrial fibrillation: age-sex standardised incidence rates per 1000 person years (py) of outcomes by database

Drug QResearch CPRD
Person years No of events Age-sex standardised rate per 1000 py (95% CI) Person years No of events Age-sex standardised rate per 1000 py (95% CI)
Major bleeding
Warfarin 39 335 1132 29.2 (27.5 to 30.9) 10 796 378 35.2 (31.6 to 38.7)
Dabigatran 1129 33 31.0 (18.8 to 43.1) 183 6 28.6 (4.2 to 53.0)
Rivaroxaban 8066 238 29.4 (25.6 to 33.1) 1143 41 34.9 (24.0 to 45.7)
Apixaban 3273 71 18.3 (13.6 to 23.1) 219 <5 5.9 (0.0 to 13.0)
Intracranial bleed
Warfarin 39 929 244 6.3 (5.5 to 7.1) 10 952 78 7.2 (5.6 to 8.8)
Dabigatran 1137 <5 2.9 (0.0 to 5.8) 184 <5 3.5 (0.0 to 10.3)
Rivaroxaban 8155 29 3.5 (2.2 to 4.8) 1156 <5 2.7 (0.0 to 5.4)
Apixaban 3297 19 5.2 (2.7 to 7.7) 220 0 NA
Haematuria
Warfarin 39 685 351 8.9 (8.0 to 9.8) 10 897 109 10.0 (8.1 to 11.9)
Dabigatran 1133 8 7.9 (2.0 to 13.8) 184 <5 8.4 (0.0 to 25.0)
Rivaroxaban 8119 71 9.0 (6.9 to 11.1) 1150 11 9.2 (3.7 to 14.7)
Apixaban 3291 21 4.3 (2.4 to 6.1) 219 <5 3.0 (0.0 to 7.2)
Haemoptysis
Warfarin 39 912 65 1.6 (1.2 to 2.0) 10 950 24 2.2 (1.3 to 3.0)
Dabigatran 1137 <5 2.3 (0.0 to 5.5) 184 0 NA
Rivaroxaban 8151 16 1.9 (1.0 to 2.9) 1155 <5 3.8 (0.1 to 7.6)
Apixaban 3300 <5 0.3 (0.0 to 0.8) 220 0 NA
All gastrointestinal bleed
Warfarin 39 684 485 12.4 (11.3 to 13.5) 10 885 171 15.9 (13.5 to 18.2)
Dabigatran 1133 19 17.7 (8.1 to 27.4) 184 <5 16.6 (0.1 to 33.1)
Rivaroxaban 8114 126 15.2 (12.5 to 17.9) 1150 22 18.8 (10.8 to 26.9)
Apixaban 3286 31 8.8 (5.2 to 12.3) 220 <5 2.9 (0.0 to 8.6)
Upper gastrointestinal bleed
Warfarin 39 719 431 11.1 (10.0 to 12.1) 10 896 152 14.1 (11.9 to 16.4)
Dabigatran 1134 16 15.6 (6.3 to 24.9) 184 <5 16.6 (0.1 to 33.1)
Rivaroxaban 8116 117 14.0 (11.5 to 16.6) 1150 22 18.8 (10.8 to 26.8)
Apixaban 3288 29 8.0 (4.6 to 11.4) 220 <5 2.9 (0.0 to 8.6)
Rectal bleed
Warfarin 39 917 62 1.6 (1.2 to 2.0) 10 949 21 1.9 (1.1 to 2.7)
Dabigatran 1136 <5 2.1 (0.0 to 4.6) 184 0 NA
Rivaroxaban 8155 9 1.1 (0.4 to 1.9) 1156 0 NA
Apixaban 3298 <5 0.7 (0.0 to 1.8) 220 0 NA
Ischaemic stroke
Warfarin 34 121 371 11.2 (10.1 to 12.4) 9459 109 11.6 (9.4 to 13.8)
Dabigatran 755 19 20.8 (10.7 to 30.9) 117 <5 21.1 (0.0 to 45.1)
Rivaroxaban 6996 83 11.8 (9.2 to 14.3) 990 9 7.9 (2.6 to 13.3)
Apixaban 2311 44 15.4 (10.6 to 20.3) 121 <5 17.5 (0.0 to 37.3)
Venous thromboembolism
Warfarin 18 496 766 41.0 (38.1 to 44.0) 4526 182 40.0 (34.2 to 45.9)
Dabigatran 1055 10 9.7 (3.5 to 15.9) 166 6 35.1 (5.0 to 65.1)
Rivaroxaban 4001 688 180.3 (166.5 to 194.1) 532 112 239.7 (193.7 to 285.8)
Apixaban 2748 89 44.0 (33.4 to 54.7) 188 <5 11.7 (0.0 to 25.0)
Mortality
Warfarin 39 960 2226 58.4 (56.0 to 60.8) 10 963 606 56.6 (52.1 to 61.1)
Dabigatran 1137 75 67.4 (41.7 to 93.0) 184 14 60.1 (26.9 to 93.2)
Rivaroxaban 8158 758 87.1 (80.8 to 93.3) 1156 130 108.4 (89.3 to 127.6)
Apixaban 3301 312 72.8 (63.9 to 81.7) 220 21 86.2 (25.4 to 146.9)

NA=not applicable.